| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
In order to prevent DNA strand separation during replication, phosphoramide mustard cyclohexanamine forms cross-linked DNA adducts, which are cytotoxic[1]. For a 48-hour period, rat spontaneously immortalized granulosa cells (SIGCs) exposed to phosphoramide mustard cyclohexanamine (3-6 μM) lose viability. Damage to ovarian DNA and the production of DNA adducts are caused by phosphoamide mustard cyclohexanamine (3-6 μM; 24-48 hours). The expression of DNA damage response (DDR) gene mRNA and DDR proteins are increased by phosphoamide mustard cyclohexanamine (3-6 μM; 24-48 hours)[1].
|
|---|---|
| ln Vivo |
Rats' subcutaneous tumor growth is inhibited by phosphoramide mustard cyclohexanamine (2.1-20.7 mg/kg; ip; daily; for 5 days)[2]. After intravenous injection (rat 59.4 mg/kg), phosphoramide mustard cyclohexanamine shows terminal elimination half-lives (rat 15.1 min)[2].
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: SIGCs Tested Concentrations: 0.5 μM, 1 μM, 3 μM, 6 μM Incubation Duration: 48 hrs (hours) Experimental Results: decreased cell viability at concentrations of 3 μM and higher. RT-PCR[1] Cell Types: SIGCs Tested Concentrations: 3 μM, 6 μM Incubation Duration: 24 hrs (hours), 48 hrs (hours) Experimental Results: Increased DDR gene mRNA expression levels. Western Blot Analysis[1] Cell Types: SIGCs Tested Concentrations: 3 μM, 6 μM Incubation Duration: 24 hrs (hours), 48 hrs (hours) Experimental Results: Generally increased DDR proteins. |
| Animal Protocol |
Animal/Disease Models: Rat, subcutaneously (sc) implanted Walker 256 carcinosarcoma tumor[2]
Doses: 2.1 mg/kg, 4.8 mg/kg , 10.4 mg/kg, 20.7 mg/kg Route of Administration: intraperitoneal (ip)injection, one time/day, for 5 days Experimental Results: Required to produce 50% inhibition of subcutaneous (sc)tumor growth with dose of 12 mg/kg. Animal/Disease Models: Rats[2] Doses: 86.0 mg/kg (pharmacokinetic/PK Analysis) Route of Administration: intravenous (iv)injection Experimental Results: T1/2 (15.1 min). |
| References |
[1]. Shanthi Ganesan, et al. Phosphoramide mustard exposure induces DNA adduct formation and the DNA damage repair response in rat ovarian granulosa cells. Toxicol Appl Pharmacol. 2015 Feb 1; 282(3): 252–258.
[2]. S Genka, et al. Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoramide mustard in the rat. Cancer Chemother Pharmacol. 1990;27(1):1-7. |
| Molecular Formula |
C10H24CL2N3O2P
|
|---|---|
| Molecular Weight |
320.20
|
| Exact Mass |
319.1
|
| Elemental Analysis |
C, 37.51; H, 7.56; Cl, 22.14; N, 13.12; O, 9.99; P, 9.67
|
| CAS # |
1566-15-0
|
| Related CAS # |
Phosphoramide mustard;10159-53-2
|
| Appearance |
Solid powder
|
| SMILES |
C1CCC(CC1)N.C(CCl)N(CCCl)P(=O)(N)O
|
| InChi Key |
BGTIPRUDEMNRIP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H13N.C4H11Cl2N2O2P/c7-6-4-2-1-3-5-6;5-1-3-8(4-2-6)11(7,9)10/h6H,1-5,7H2;1-4H2,(H3,7,9,10)
|
| Chemical Name |
amino-[bis(2-chloroethyl)amino]phosphinic acid;cyclohexanamine
|
| Synonyms |
PMC; NSC-69945; NSC 69945; NSC69945; Phosphoramide Mustard cyclohexylammonium salt
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~312.3 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (312.30 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1230 mL | 15.6152 mL | 31.2305 mL | |
| 5 mM | 0.6246 mL | 3.1230 mL | 6.2461 mL | |
| 10 mM | 0.3123 mL | 1.5615 mL | 3.1230 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
